Products from BPS Bioscience require a minimum order value above 400€Encompassing Amino Acids: full length
Applications: Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
Assay Conditions: 25 mM of Tris-HCl , pH 8.0, 137 mM of NaCl, 2.7 mM of KCl, 1 mM of MgCl
2, 0.1 mg/ml BSA, 20 µM substrate , BPS catalog #: 50037, and HDAC2, at 37°C, 30 min. followed by incubation with HDAC developer (Catalog #50030) for 15 min at RT. Fluorescence intensity is measured at ex360/em460.
Description: Human HDAC2 , GenBank Accession No. NM_001527, full length with C-terminal His-tag, MW= 56 kDa, expressed in baculovirus expression system.
Format: Aqueous buffer solution
Formulation: 40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% glycerol, 200 mM imidazole
Genbank: NM_001527
Host Cell Line: Sf9 cells
Storage Stability: At least 6 months at -80°C.
Tags: C-terminal His-tag
Uniprot: Q92769
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Yang,W.M. et al., Proc. Natl. Acad. Sci. U.S.A. 93 (23), 12845-12850 (1996).
2. Mungall, A.J. et al., Nature 425 (6960), 805-811 (2003).Application References:
1. Jang, S., et al. Cancer Gene Ther. 2015 Aug;22(8):410-6. doi: 10.1038/cgt.2015.37. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation (2015)
2. Wang, Y., et al. Chem Biol. 2015 Feb 19;22(2):273-84. doi: 10.1016/j.chembiol.2014.12.015. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015)
3.
Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction (2015)
4. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014)
5. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014)
6. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014)
7. Wang, C., et al. J Med Chem. 2014 Oct 9;57(19):7999-8009. doi: 10.1021/jm500872p. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014)
8. Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging (2014)
9. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014)
10. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014)
11. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013)
12. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013)
13.Fass, D.M., et al. Neuropharmacology. 2013 Jan; 64: 81–96. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013)
14. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013)
15. Baud, MGJ, et al. ChemMedChem. 2013 Jan;8(1):149-56. doi: 10.1002/cmdc.201200450. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013)
16. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹¸F-FAHA (2013)
Pavlik, C.M., et al. J Nat Prod. 2013 Nov 22;76(11):2026-33. doi: 10.1021/np400198r. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013)
18. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E (2013)
English
Deutsch
